The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Anti-Neprilysin drugs are used in the treatment of heart failure and other cardiovascular diseases by inhibiting the neprilysin enzyme which degrades natriuretic peptides. Natriuretic peptides help in regulating blood pressure and flow along with sodium and water balance in the body. Inhibition of neprilysin helps increase the levels of natriuretic peptides in the body thereby providing cardiovascular benefits. The anti-neprilysin drug Sacubitril/Valsartan approved under trade name Entresto is the first in class drug approved for treatment of heart failure.
Market key trends:
The increasing geriatric population is one of the key trends driving the growth of the anti-neprilysin market. As per the United Nations data, the global geriatric population aged 60 years and above is expected to more than double from 962 million in 2017 to around 2.1 billion by 2050. Elderly population is more prone to developing chronic diseases like heart failure. With the growing elderly demographics, the prevalence of heart failure and other cardiovascular disorders is also rising significantly globally. This in turn is increasing the demand and adoption of anti-neprilysin drugs like Entresto for treatment of such conditions thus propelling the market growth during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the anti-Neprilysin market is moderate as there are high costs associated with R&D and clinical trials.
Bargaining power of buyers: The bargaining power of buyers is high due to the availability of substitutes. Buyers can switch to alternative medication easily.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are few players controlling the supply of raw materials.
Threat of new substitutes: The threat of new substitutes is high as other medications can be used for treating cardiovascular and renal diseases.
Competitive rivalry: The competitive rivalry in the market is high due to the presence of few major players.
Key Takeaways
The global anti-Neprilysin market is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing prevalence of cardiovascular and renal diseases.
Regional analysis
North America is expected to dominate the global anti-Neprilysin market during the forecast period. The high growth in the region can be attributed to growing elderly population and rising healthcare expenditure. Asia Pacific is anticipated to exhibit the fastest growth rate over the next few years owing to increasing awareness regarding cardiovascular disorders.
Key players
Key players operating in the anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. BIOPROJET has a strong pipeline of candidates to treat heart failure and renal diseases. Novartis AG focuses on developing novel formulations to enhance drug efficacy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
